Rapid Dose Therapeutics Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA75339A1012
CAD
0.16
-0.05 (-23.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.72
2

The company has declared Negative results for the last 4 consecutive quarters

3

Risky - Negative EBITDA

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 21 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.56

stock-summary
Return on Equity

91.50%

stock-summary
Price to Book

-3.86

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - May 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.11%
0%
-11.11%
6 Months
-38.46%
0%
-38.46%
1 Year
-27.27%
0%
-27.27%
2 Years
6.67%
0%
6.67%
3 Years
-20.0%
0%
-20.0%
4 Years
-44.83%
0%
-44.83%
5 Years
-34.69%
0%
-34.69%

Rapid Dose Therapeutics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-78.88%
EBIT Growth (5y)
-164.79%
EBIT to Interest (avg)
-0.73
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
-2,127.70
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6,711.89%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.98
EV to EBIT
-6.50
EV to EBITDA
-7.05
EV to Capital Employed
-10.39
EV to Sales
9.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - May'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "May'25",
        "Nov'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.50",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-1.00",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-1.40",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-644.00%",
          "val2": "-2,026.60%",
          "chgp": "138.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Feb'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Feb 2025 is 110.00% vs 42.86% in Feb 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Feb 2025 is -25.58% vs -13.16% in Feb 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Feb'25",
        "Feb'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.10",
          "val2": "1.00",
          "chgp": "110.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.90",
          "val2": "-2.50",
          "chgp": "-56.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.70",
          "chgp": "71.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.40",
          "val2": "-4.30",
          "chgp": "-25.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,000.70%",
          "val2": "-3,021.60%",
          "chgp": "102.09%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - May'25 - QoQstock-summary
May'25
Nov'24
Change(%)
Net Sales
0.80
0.50
60.00%
Operating Profit (PBDIT) excl Other Income
-0.40
-1.00
60.00%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-1.40
50.00%
Operating Profit Margin (Excl OI)
-644.00%
-2,026.60%
138.26%
USD in Million.
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Consolidated) - Feb'25stock-summary
Feb'25
Feb'24
Change(%)
Net Sales
2.10
1.00
110.00%
Operating Profit (PBDIT) excl Other Income
-3.90
-2.50
-56.00%
Interest
1.20
0.70
71.43%
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-5.40
-4.30
-25.58%
Operating Profit Margin (Excl OI)
-2,000.70%
-3,021.60%
102.09%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Feb 2025 is 110.00% vs 42.86% in Feb 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Feb 2025 is -25.58% vs -13.16% in Feb 2024

stock-summaryCompany CV
About Rapid Dose Therapeutics Corp. stock-summary
stock-summary
Rapid Dose Therapeutics Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available